PALO ALTO, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) (the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that Dr. William (Wei) Cao, Chief Executive Officer of the Company, will present "48-week Clinical Results from Phase IIa Trial of Human Adipose Mesenchymal Progenitor Cell (haMPC) Treatment for Knee Osteoarthritis" at the 10th Annual World Stem Cell Summit (WSCS) and RegMed Capital Conference (RMCC) held at the Marriott Rivercenter, San Antonio, Texas, December 3-5, 2014.
"We look forward to discussing the data analysis comprising of WOMAC, NRS-11, SF-36 and KSCRS indices. We will also share the knee articular cartilage volume assessment through 3D SPGR quantitative magnetic resonance imaging (MRI) evaluation. Our participation in the Summit is an excellent opportunity for us to meet with other key opinion leaders and potential partners within the regenerative medicine and stem cell industry, in order to contribute to the advancement of medical therapies which could improve the quality of life for countless patients and their families," commented Dr. Cao.
The conference brings together prominent industry leaders, scientists, clinicians, regulators, policymakers, economic development officers and law and ethics experts in the fields of stem cell and regenerative medicine. Conference sessions will focus on advancing stem cell and regenerative medicine science and translation into clinical trials and medical therapies for degenerative diseases and severe injuries.
Dr. Cao will present his speech on Friday, December 5th at 2:00pm, announcing the results from the Company's 48-week follow-up data analysis of its Phase IIa clinical trial for Rejoin™ proprietary regenerative medicine treatment of Knee Osteoarthritis (KOA). The Company previously announced statistically relevant 6-month follow-up data from the trial, which revealed a consistent increase in cartilage volume of the whole joint beginning as early as three months after the therapy.
About Knee Osteoarthritis
According to the Foundation for National Institutes of Health (FNIH), there are 27 million Americans with Osteoarthritis (OA), and symptomatic Knee Osteoarthritis (KOA) occurs in 13% of persons over 60 years of age. The International Journal of Rheumatic Diseases, 2011 reports approximately 57 million people in China suffering from KOA. Currently no treatment exists that can effectively preserve knee joint structure or slow the progression of KOA. Current common drug-based methods of management, including anti-inflammatory medications (NSAIDs), only provide relief of symptoms accompanied by the risk of side effects. The mobility of patients with KOA is compromised, leading to sedentary lifestyle and increases all causes of mortality, doubles the risk of cardiovascular diseases, diabetes, and obesity, and increases the risks of colon cancer, high blood pressure, osteoporosis, lipid disorders, depression and anxiety. According to Epidemiology of Rheumatic Disease (Silman AJ, Hochberg MC. Oxford Univ. Press, 1993:257) 53% of KOA patients will eventually become disabled.
About the Clinical Trial
Cellular Biomedicine Group's Phase IIa clinical trial studies the safety and efficacy of CBMG's proprietary adipose-derived mesenchymal progenitor cell (haMPC)-based therapy (ReJoinTM) for knee osteoarthritis. The trial is conducted by Shanghai's Renji Hospital, a tertiary hospital affiliated with Shanghai Jiao Tong University School of Medicine. ReJoinTM therapy for KOA is an interventional therapy that consists of 30ml of adipose (fat) tissue obtained via lipoaspiration from the patient, from which the patient's vascular stromal cells (VSC; a combination of several types of monocytes including mesenchymal stem cells) are isolated using CBMG's proprietary medical device, the A-Stromal Kit, which produces a high yield of VSC, and haMPCs are then expanded using CBMG's proprietary culture medium. After three weeks there is an initial injection into the knee joints and a second injection three weeks later.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 email@example.com Vivian Chen Managing Director Investor Relations, Grayling +1 646 284-9427 firstname.lastname@example.org
Source:Cellular Biomedicine Group Inc.